PREEMPTIVE THERAPY WITH COLCHICINE IN PATIENTS OLDER THAN 60 YEARS WITH HIGH RISK OF SEVERE PNEUMONIAE DUE TO CORONAVIRUS
Status:
Recruiting
Trial end date:
2021-12-31
Target enrollment:
Participant gender:
Summary
This is a phase 3 clinical trial, randomized, single-center, opened, controlled, to evaluate
efficacy and safety of early administration of colchicines in patients older than 60 years,
with high risk of pulmonary complications due to coronavirus SARS-CoV2 (COVID-19). An
approximately number of 954 subjects meeting all inclusion and none exclusion criteria will
be randomized either to receive colchicines or symptomatic treatment with paracetamol during
21 days.
Phase:
Phase 3
Details
Lead Sponsor:
Instituto de Investigación Marqués de Valdecilla
Collaborators:
Gerencia Atencion Primaria Area 3 Gerencia de atención primaria área 1 Gerencia de atención primaria área 2 Gerencia de atención primaria área 4